Supplemental Table S4 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer

Supplemental Table S4 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer

<p>All Mutations Identified in One-Year Samples</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Christopher J. Gibson (15907642) (author)
Drugi avtorji:	Geoffrey Fell (15136208) (author), Tal Sella (15907645) (author), Adam S. Sperling (15907648) (author), Craig Snow (15907651) (author), Shoshana M. Rosenberg (15907654) (author), Greg Kirkner (15907657) (author), Ashka Patel (15907660) (author), Deborah Dillon (15907663) (author), Alexander G. Bick (15127852) (author), Donna Neuberg (15038318) (author), Ann H. Partridge (9467249) (author), Peter G. Miller (15907666) (author)
Izdano:	2025
Teme:	Cancer Tumor Biology Cancer Detection and Diagnosis Biomarkers Cancer risk biomarkers Breast Cancer Tumor Evolution
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Supplemental Table S3 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
od: Christopher J. Gibson (15907642)
Izdano: (2025)

Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
od: Yeh Wang (14964041)
Izdano: (2025)

Supplemental Table S4 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
od: Yeh Wang (14964041)
Izdano: (2025)

Supplementary Data from Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics
od: Yuan Chun Ding (16721349)
Izdano: (2025)

Supplementary Table 3_Clonal distribution analysis from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
od: Niccolò Roda (16437288)
Izdano: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
od: Lavanya Sivapalan (15314248)
Izdano: (2025)

Table S1 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
od: Lenka Stolarova (16547259)
Izdano: (2025)

Table S2 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
od: Lenka Stolarova (16547259)
Izdano: (2025)

Table S3 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
od: Lenka Stolarova (16547259)
Izdano: (2025)

Supplementary Data from Genome-Wide Analysis of Rare Haplotypes Associated with Breast Cancer Risk
od: Fan Wang (14963418)
Izdano: (2025)

Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
od: Javier Pascual (15018176)
Izdano: (2025)

Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
od: Javier Pascual (15018176)
Izdano: (2025)

Supplementary Figure S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
od: Javier Pascual (15018176)
Izdano: (2025)

Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
od: Javier Pascual (15018176)
Izdano: (2025)

Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
od: Javier Pascual (15018176)
Izdano: (2025)

Supplementary Table S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
od: Javier Pascual (15018176)
Izdano: (2025)

Supplementary Table S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
od: Javier Pascual (15018176)
Izdano: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
od: Milana A. Bergamino (15038015)
Izdano: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
od: Milana A. Bergamino (15038015)
Izdano: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
od: Milana A. Bergamino (15038015)
Izdano: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
od: Milana A. Bergamino (15038015)
Izdano: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
od: Milana A. Bergamino (15038015)
Izdano: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
od: Milana A. Bergamino (15038015)
Izdano: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Table S1-S3 from Clonal Hematopoiesis Mutations in Patients with Lung Cancer Are Associated with Lung Cancer Risk Factors
od: Wei Hong (432102)
Izdano: (2025)

Supplementary Table 10_Pro metastatic pathways identified by classification analysis from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
od: Niccolò Roda (16437288)
Izdano: (2025)

Supplementary Table S2 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
od: Holly Tovey (16824233)
Izdano: (2025)

Supplementary Table S3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
od: Holly Tovey (16824233)
Izdano: (2025)

Supplementary Table 1_Primer and shRNA sequences_PCR cycles_Mycoplasma testing from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
od: Niccolò Roda (16437288)
Izdano: (2025)

Supplementary Table 2_Predictive power of genes and signatures_Patient cohorts GEO accession number from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
od: Niccolò Roda (16437288)
Izdano: (2025)

Supplementary Table 6_Gene modules analysis_GO and curated pathways associated to gene modules from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
od: Niccolò Roda (16437288)
Izdano: (2025)

Supplementary Table 8_Genes identified by classification analysis in pro vs non metastatic clones from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
od: Niccolò Roda (16437288)
Izdano: (2025)

Supplementary Table 9_Pro metastatic pathways identified by differential expression singlePT setting from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
od: Niccolò Roda (16437288)
Izdano: (2025)

Supplementary Table 7_Genes identified by differential expression analysis in pro vs non metastatic clones from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
od: Niccolò Roda (16437288)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ile7ioupu7cd54jfpbobnm9hcd